Why it was important not to abandon antiviral R&D, in favor of the emerging Covid-19 vaccines
The diagram at left illustrates a synergystic response generated through dosing of Mebendazole (Vermox), a drug used to treat roundworm and whipworm infections in humans, on the viral lifecycle of Covid19, and other pathogens. This antiparasitic drug interrupts Covid's ability to trick human cells into believing they are not being invaded, and thereby allowing Covid rna to rapidly multiply and spread. This is just one of dozens of broad-spectrum antiviral therapeutics that were available to the US and other nations, when the pandemic first hit.
But by focusing funding, media and government attention solely on vaccines - a runaway train of public opinion and emotion - leadership unintentionally (we hope) abandoned those currently infected or at risk from Covid. Some 7 million in the US, it would turn out. Leadership knew worldwide that it would take years to perfect a workable vaccine and that traditional military / medical countermeasures (MCM) response to any public health emergency always called for treatment and cure focus FIRST - for this reason; and vaccines came LAST.
The entire emphasis of funding the first two years of the pandemic - was to abandon current victims in favor of 'potential' victims later on down the road. When it would have been so simple to begin urgent AI trials on at least 24 antivirals immediately identified. We were a part of this first wave of research; and have remained strong advocates to FDA, Congressional and US and EU, UK agencies; for the advancement of strong antiviral pathogen response for both Covid and for future pathogen risks. Including TB, a growing world concern.
The US Military, like UNESCO and Oxfam and the ICRC and other global leaders in emergency response - and BigPharma are NOT emergency responders - have a motto, which is what Canada and others articulated repeatedly, to no avail:
the DC
Strategic Group
PARTNERS
SOLUTIONS
©2025 DC Strategic Group l DSG Global. All rights reserved
Washington DC l London